Clinical Trials Logo

Citation(s)

Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features

Details for clinical trial NCT00103207